Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.

Hart MP, Brettschneider J, Lee VM, Trojanowski JQ, Gitler AD.

Acta Neuropathol. 2012 Aug;124(2):221-30. doi: 10.1007/s00401-012-0985-5.

2.

Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts.

Van Langenhove T, van der Zee J, Engelborghs S, Vandenberghe R, Santens P, Van den Broeck M, Mattheijssens M, Peeters K, Nuytten D, Cras P, De Deyn PP, De Jonghe P, Cruts M, Van Broeckhoven C.

Neurobiol Aging. 2012 May;33(5):1004.e17-20. doi: 10.1016/j.neurobiolaging.2011.09.025.

PMID:
22035589
3.

The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.

Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, Geisen C, Gitler AD, Becker T, Weber M, Berg D, Andersen PM, Krüger R, Riess O, Ludolph AC, Auburger G.

Neurobiol Dis. 2012 Jan;45(1):356-61. doi: 10.1016/j.nbd.2011.08.021.

PMID:
21889984
4.

Understanding the role of TDP-43 and FUS/TLS in ALS and beyond.

Da Cruz S, Cleveland DW.

Curr Opin Neurobiol. 2011 Dec;21(6):904-19. doi: 10.1016/j.conb.2011.05.029. Review.

5.

Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis.

Chen Y, Huang R, Yang Y, Chen K, Song W, Pan P, Li J, Shang HF.

Neurobiol Aging. 2011 Oct;32(10):1925.e1-5. doi: 10.1016/j.neurobiolaging.2011.05.015.

PMID:
21741123
6.

Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis.

Daoud H, Belzil V, Martins S, Sabbagh M, Provencher P, Lacomblez L, Meininger V, Camu W, Dupré N, Dion PA, Rouleau GA.

Arch Neurol. 2011 Jun;68(6):739-42. doi: 10.1001/archneurol.2011.111.

PMID:
21670397
7.

ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion.

Sorarù G, Clementi M, Forzan M, Orsetti V, D'Ascenzo C, Querin G, Palmieri A, Ermani M, Angelini C, Pegoraro E.

Neurology. 2011 Jun 7;76(23):2030-1. doi: 10.1212/WNL.0b013e31821e557a. No abstract available.

PMID:
21646631
8.

Ataxin-2 repeat-length variation and neurodegeneration.

Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, DeJesus-Hernandez M, Adamson J, Li M, Volkening K, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Woodruff BK, Knopman DS, White CL 3rd, Van Gerpen JA, Meschia JF, Mackenzie IR, Boylan K, Boeve BF, Miller BL, Strong MJ, Uitti RJ, Younkin SG, Graff-Radford NR, Petersen RC, Wszolek ZK, Dickson DW, Rademakers R.

Hum Mol Genet. 2011 Aug 15;20(16):3207-12. doi: 10.1093/hmg/ddr227.

9.

Amyotrophic lateral sclerosis and spinocerebellar ataxia 2.

Fischbeck KH, Pulst SM.

Neurology. 2011 Jun 14;76(24):2050-1. doi: 10.1212/WNL.0b013e31821f4498. No abstract available.

PMID:
21562249
10.

Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2.

Van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught PW, Thijs V, Dubois B, Matthijs G, van den Berg LH, Robberecht W.

Neurology. 2011 Jun 14;76(24):2066-72. doi: 10.1212/WNL.0b013e31821f445b.

PMID:
21562247
11.

A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport.

Pesiridis GS, Tripathy K, Tanik S, Trojanowski JQ, Lee VM.

J Biol Chem. 2011 May 27;286(21):18845-55. doi: 10.1074/jbc.M111.231118.

12.

Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.

Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, de Carvalho M, Meyer T, Tysnes OB, Auburger G, Gispert S, Bonini NM, Andersen PM, Gitler AD.

Hum Mol Genet. 2011 May 1;20(9):1697-700. doi: 10.1093/hmg/ddr045.

13.

TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1.

McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, Rouleau GA, Vande Velde C.

Hum Mol Genet. 2011 Apr 1;20(7):1400-10. doi: 10.1093/hmg/ddr021.

14.

Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy.

Liachko NF, Guthrie CR, Kraemer BC.

J Neurosci. 2010 Dec 1;30(48):16208-19. doi: 10.1523/JNEUROSCI.2911-10.2010.

15.

Modulation of stress granules and P bodies during dicistrovirus infection.

Khong A, Jan E.

J Virol. 2011 Feb;85(4):1439-51. doi: 10.1128/JVI.02220-10.

16.

Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1.

Brady OA, Meng P, Zheng Y, Mao Y, Hu F.

J Neurochem. 2011 Jan;116(2):248-59. doi: 10.1111/j.1471-4159.2010.07098.x.

17.

Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies.

Miguel L, Frébourg T, Campion D, Lecourtois M.

Neurobiol Dis. 2011 Feb;41(2):398-406. doi: 10.1016/j.nbd.2010.10.007.

PMID:
20951205
18.

Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue.

Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, Petrucelli L, Wolozin B.

PLoS One. 2010 Oct 11;5(10):e13250. doi: 10.1371/journal.pone.0013250. Erratum in: PLoS One. 2011;6(9). doi: 10.1371/annotation/7d880410-06e3-4fe3-a8f1-e84c89bcf8d0. Vanderwyde, Tara [corrected to Vanderweyde, Tara].

19.

RNA granules: the good, the bad and the ugly.

Thomas MG, Loschi M, Desbats MA, Boccaccio GL.

Cell Signal. 2011 Feb;23(2):324-34. doi: 10.1016/j.cellsig.2010.08.011. Review.

20.

Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.

Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rüb U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitler AD.

Nature. 2010 Aug 26;466(7310):1069-75. doi: 10.1038/nature09320.

Items per page

Supplemental Content

Support Center